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Abstract The Gly^Ala repeat (GAr) of the Epstein^Barr virus
nuclear antigen 1 is a cis acting inhibitor of ubiquitin^proteasome
proteolysis. We have investigated the capacity of various repeats
to inhibit the turnover of the proteasomal substrate IUBK.
Inhibition of TNFK-induced degradation was achieved by
insertion of octamers containing three alanines or valines,
interspersed by no more then three consecutive glycines. The
inhibitory activity was abolished by increasing the length of the
spacer, by eliminating the spacers, or by substitution of a single
hydrophobic residue with a polar or charged residue. A serine
containing octamer was inactive but inhibition was partially
restored by insertion of three consecutive repeats. These findings
suggest a model where inhibition requires the interaction of at
least three alanine residues of the GAr in a L-strand conforma-
tion with adjacent hydrophobic binding pockets of a putative
receptor. ß 2001 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Ubiquitin^proteasome dependent proteolysis is involved in
the regulation of cellular processes such as cell cycle progres-
sion, transcription, tissue development and atrophy, £ux of
substrates through metabolic pathways, selective elimination
of abnormal proteins, and processing of intracellular antigens
for presentation to MHC class I restricted CTLs (reviewed in
[1,2]).
Intracellular parasites, such as viruses, have developed
strategies to interfere with this proteolytic machinery by in-
teracting with various components of the pathway [3^12]. A
particularly interesting example of a viral protein that targets
the ubiquitin^proteasome pathway is the Epstein^Barr virus
(EBV) nuclear antigen-1 (EBNA1). EBNA1 contains an inter-
nal repeat exclusively composed of glycines and alanines
(GAr) that inhibits in cis the presentation of endogenous anti-
gens to MHC class I restricted cytotoxic T-lymphocytes
(CTLs) [13] and prevents ubiquitin^proteasome dependent
proteolysis in vitro [14]. EBNA1 is the only EBV protein
that is ubiquitously expressed in all EBV-associated malignan-
cies [15], and its resistance to CTL recognition could play an
important role in the maintenance of EBV latency. Interest-
ingly, proteins from other human and primate Q-herpesviruses,
such as the EBNA1 homologs of the baboon and rhesus mon-
key lymphocryptoviruses (BaLCV and RhLCV) [16], and the
latency-associated nuclear antigen (LANA) of Kaposi sarco-
ma herpes virus (KSHV) [17,18], also contain repetitive do-
mains of di¡erent lengths and sequences, suggesting that the
repeats may play a common role in the biology of these vi-
ruses.
The mechanism whereby the GAr in£uences ubiquitin^pro-
teasome dependent proteolysis is not fully understood. Using
as indicator IUBK, a known target of this proteolytic pathway
[19], we have identi¢ed an eight amino acid long GAr poly-
peptide, GGAGAGAG, as the minimal sequence required for
the inhibitory e¡ect [20]. An IUBK chimera containing the
repeat was phosphorylated and ubiquitinated in response to
tumor necrosis factor K (TNFK), but was then released from
complexes with NF-UB and failed to associate with the pro-
teasome. In addition, insertion of this inhibitory sequence in
di¡erent positions of IUBK decreased its basal turnover in
vivo, resulting in constitutive dominant-negative mutants.
In the present study, we have investigated the relationship
between the inhibitory activity and the amino acid composi-
tion of the repeat. We demonstrated that inhibitory repeats
contain at least three hydrophobic amino acids interspersed
by no more then three consecutive glycine residues. The in-
hibitory activity was abolished by substitution of a single
hydrophobic residue of the octamer with the polar amino
acid serine but the e¡ect could be partially compensated by
increasing the length of the repeat.
2. Materials and methods
2.1. Plasmids
The strategy for construction of IUBK chimeras carrying N-terminal
repeats was previously described [20]. Brie£y, a human IUBK gene
tagged with three in£uenza virus hemagglutinin epitopes (HA)
[21,22] was cloned in the HindIII and XbaI sites of the pSP64-polyA
vector (Promega). The NotI^XbaI region of the vector downstream of
the IUBK stop codon was substituted with the NotI^TAG^XbaI linker
sequence to remove the SalI site located in the polylinker. Synthetic
oligonucleotides with 3P overlapping ends encoding GAr sequences
and substitution analogues were annealed at 42‡C in 10 mM MgCl2,
20 mM Tris^HCl pH 8.0, 2 mM DTT. The complementary strands
were synthesized by Klenow enzyme. The resulting DNA fragments
were digested with SalI and XhoI and cloned into the remaining
unique SalI site located between the start codon of IUBK and the
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HA tag. The identity of the chimeras was in each case con¢rmed by
DNA sequencing. For transfection experiments the chimeric HA-
IUBK genes were recloned into the pRc/CMV eukaryotic expression
vector (Invitrogen).
2.2. Cells, transfection and protein analysis
The human cervical carcinoma line HeLa was maintained in Isco-
vec’s modi¢ed Eagle’s medium containing 10% (v/v) fetal calf serum,
100 IU/ml penicillin and 100 Wg/ml streptomycin. 70^80% con£uent
monolayers were transfected with a mixture of 1% w/v plasmid DNA
and 0.6% w/v Lipofectamine (Life Technologies) according to stan-
dard protocols. The transfected cells were cultured for 48 h before
treatment with 100 ng/ml recombinant human TNFK (Boehringer
Mannheim). At the indicated time of treatment, the plates were placed
on ice and the monolayers were washed with ice-cold phosphate-bu¡-
ered saline (PBS). Cell lysis, pulse-chase and Western blots experi-
ments were performed as described before [20].
3. Results
3.1. The GAr of EBNA1 contains multiple inhibitory octamer
motifs
We have previously shown that insertion of the octamer
peptide GGAGAGAG in di¡erent positions of IUBK is su⁄-
cient to inhibit TNFK-induced proteolysis in vivo [20]. The
inhibitory activity was lost when the length of the insert was
reduced to four amino acids. Since the inactive inserts,
GAGA and GAGG, contained two or one alanine residues,
respectively, we hypothesized that the inhibitory motif should
contain three or more alanines. The 238 amino acid long full
length GAr of the prototype B95.8 EBNA1 (£GA) does not
contain adjacent alanine residues. We generated, therefore, a
set of all the possible octamers that contain three alanines
separated by variable numbers of glycines (Table 1). Octamers
containing the same core sequence, Ala^Glyn^Ala^Glyn^Ala,
Fig. 1. Schematic representation of the chimeric IUBK constructs.
The coding sequence of IUBK is shown as an open box with the ¢ve
ankyrin repeats (AR) indicated by hatched boxes and the coding re-
gion for three in£uenza hemagglutinin epitopes (HA) indicated by a
¢lled box. The lysines, K21 and K22, and serines, S32 and S36, in-
volved in signal dependent phosphorylation and ubiquitination are
indicated. Cassettes encoding repeats of di¡erent length and amino
acid composition were inserted in frame at the N-terminal end im-
mediately after the HA tag (position 37).
Table 1
Sequence of predicted GAr octamers containing three alanine resi-
dues interspersed by variable numbers of glycines and their repre-
sentation in EBNA1
Octamer (x-y)a Sequenceb Non-overlapping octamers
in EBNA1c
1-1 AGAGAGGG 1
GAGAGAGG 0
GGAGAGAG 1
GGGAGAGA 0
1-2 AGAGGAGG 11
GAGAGGAG 11
GGAGAGGA 11
1-3 AGAGGGAG 11
GAGAGGGA 11
1-4 AGAGGGGA 0
2-1 AGGAGAGG 19
GAGGAGAG 19
GGAGGAGA 16
2-2 AGGAGGAG 12
GAGGAGGA 12
2-3 AGGAGGGA 0
3-1 AGGGAGAG 6
GAGGGAGA 6
3-2 AGGGAGGA 9
4-1 AGGGGAGA 0
aThe octamers are named according the number of glycines between
the ¢rst and second (x) and second and third (y) alanine residue.
bOctamers containing the same Ala^Glyn^Ala^Glyn^Ala core motif
but di¡erent numbers of £anking glycines were considered as syno-
nyms.
cThe 239 amino acid long GAr of the prototype B95.8-encoded
EBNA1 was searched for exact matches to each possible sequence.
Fig. 2. Inhibition of TNFK-induced proteasomal degradation of
IUBK by insertion of GAr octamers with di¡erent Gly spacers.
HeLa cells transiently transfected with HA-tagged IUB-GAr chime-
ras were cultured for 48 h before treatment with 100 ng/ml TNFK
for the indicated time. A: Western blots of total cell extracts were
probed with an anti-HA mAbs. One representative experiment out
of three is shown. B: The intensity of the HA-IUB-GAr speci¢c
bands was quanti¢ed by densitometry. The amount of residual IUB-
GAr after 15 min treatment was calculated as the ratio between the
intensity of the speci¢c band in treated and untreated cells.
Mean þ S.D. of three experiments.
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but di¡erent numbers of N- and C-terminal glycines were
considered as synonyms. Only one copy of the GGAGAGA
octamer was identi¢ed in the £GA sequence using the PatScan
algorithm (http://www-unix.mcs.anl.gov/compbio/PatScan/
HTML/patscan.htm), whereas the octamers GAGGAGAG,
GGAGGAGA, GAGAGGAG, GAGAGGGA, and GAGG-
GAGA were present 19, 16, 11, 11 and 9 times, respectively
(Table 1). Many of the theoretically possible octamers were
not found, indicating that there may be restrictions in the
expression of these sequences.
A set of hemagglutinin-tagged IUBK chimeras was con-
structed to test the in£uence of di¡erent EBNA1 derived oc-
tamers on the TNFK-induced degradation of IUBK (Fig. 1).
Three octamer peptides GAGAGGAG, GAGGAGAG and
AGGAGGAG had cis stabilizing e¡ects comparable to that
of the prototype GGAGAGAG sequence (Fig. 2, panels 1-2,
2-1 and 2-2). A weaker inhibition was observed with the GA-
GAGGGA and GAGGGAGA peptides (Fig. 2, panels 1-3
and 3-1). Alignment of the inserts suggests that the distance
between alanine residues may be important for the inhibitory
activity. In accordance, a chimera containing a N-terminal
octamer where the ¢rst and second alanine residues were sep-
arated by four glycines showed weaker inhibitory activity only
marginally stronger than that obtained by insertion of a con-
trol eight amino acid long glycine polypeptide (Fig. 2, panel 4-
1). We next asked whether the spacing itself might be impor-
tant for the e¡ect. Insertion of three alanine residues, or of an
octamer containing three consecutive alanines £anked by gly-
cines, did not prevent TNFK-induced proteolysis (Fig. 3, pan-
els 1 and 2). Polyalanine inserts of four or six amino acids
were also inactive whereas partial protection was achieved
with an eight alanine long insert (Fig. 3, panels 3^5).
3.2. Hydrophobic residues are required for the inhibitory e¡ect
Additional experiments were performed to evaluate the im-
pact of hydrophobicity on the stabilizing e¡ect of the repeats.
Substitution of the three alanines in the peptide GGAGA-
GAG with the polar serine residues abolished the protective
activity (Fig. 4). In accordance with the predicted requirement
of at least three alanine residues, the inhibiting activity was
lost already after the substitution of a single alanine for serine.
Similarly, substitution of the central alanine in the peptide
AGGAGGAG with the charged residue aspartic acid abol-
ished the protective activity. We then tested whether alanine
could be substituted by other hydrophobic amino acids. As
shown in Fig. 4, the inhibitory activity was maintained when
all the alanines were changed to the next residue in the scale
of hydrophobicity, valine. The GGVGVGVG chimera was as
stable as the chimera containing the prototype inhibitor se-
quence.
Fig. 3. Gly residues are required for optimal inhibitory activity.
HeLa cells were transfected with HA-tagged IUBK chimeras contain-
ing the indicated inserts. Poly-alanine inserts of three, four, six and
eight amino acids were compared with the prototype inhibitory oc-
tamer GAGAGGAG (positive control) and with an eight amino
acid long polyglycine (negative control). A: One representative
Western blot is shown in the ¢gure. B: Degradation of the chimeras
after treatment with TNFK and the amount of residual IUBK after
treatment for 15 min were measured as described in the legend to
Fig. 1. Mean þ S.D. of three experiments.
Fig. 4. Hydrophobic amino acids are required for the inhibitory ac-
tivity. HeLa cells were transfected with IUBK chimeras containing
octamers where one Ala residue was substituted by Ser (4) or Asp
(5) or all three Ala were substituted with Ser (3) or Val (6). The
non-inhibitory polyglycine (1) and the GGAGAGAG octamer (2)
served as negative and positive controls, respectively. A: One repre-
sentative Western blot is shown in the ¢gure. B: Degradation of the
chimeras after treatment with TNFK, and the amount of residual
IUBK after treatment for 15 min, were measured as described in the
legend to Fig. 1. Mean þ S.D. of three experiments.
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3.3. Length dependent inhibition of IUBK turnover by variant
repeats
In addition to signal dependent proteolysis, the ubiquitin^
proteasome pathway is also implicated in the physiological
turnover of several cellular proteins, including IUBK (reviewed
in [23,24]). This type of regulated proteolysis proceeds with a
signi¢cantly shower kinetics, probably due to the involvement
of a di¡erent family of ubiquitin conjugating enzymes and
slower rate of ubiquitination [25^29]. In accordance with pre-
vious observations [20], the half-life of IUBK, was approxi-
mately 30 min while introduction of the GAGAGGAG repeat
resulted in a half-life in excess of 12 h (Fig. 5, and data not
shown). In accordance with the failure to prevent TNFK-in-
duced proteolysis, the physiological turnover of IUBK was not
altered by insertion of the GGSGAGAG sequence. However,
signi¢cant stabilization was induced by insertion of a longer
polypeptide containing three GGSGAGA motifs. We ¢nally
tested whether increasing the length of the repeat could com-
pensate the detrimental e¡ect of the serine substitution on
TNFK-induced degradation. As expected, an IUBK chimera
containing a 24 amino acid long polypeptide with three GGA-
GAGAG motifs was completely resistant to TNFK-induced
degradation (Fig. 6). In contrast, insertion of a serine contain-
ing repeat of similar length had no signi¢cant e¡ect resulting
in an half-life only marginally longer than that achieved by
insertion of a 24 residue long polyglycine.
4. Discussion
The GAr of the EBV nuclear antigen EBNA1 is the ¢rst
example of protein domain that acts as a cis-inhibitor of
ubiquitin^proteasome dependent proteolysis. We have previ-
ously shown that an eight amino acid long GAr inhibits the
TNFK-induced degradation of IUBK by preventing stable in-
teraction of the ubiquitinated substrate with the proteasome
[20]. In the present study, we found a clear relationship be-
tween the distance of the three key alanine residues and the
inhibitory e¡ect. We have also found that a small hydropho-
bic amino acid, such as valine, can substitute for alanine with-
out loss of inhibitory e¡ect. The need of three hydrophobic
Fig. 5. Impact of length on the inhibitory activity of variant repeats
containing Ser residues. Transfected HeLa cells were metabolically
labelled and then chased in isotope free medium for the indicated
time before immunoprecipitation with the anti-HA antibody and
separation by SDS^PAGE. The amino acid sequences of the inserts
are shown on the top. A: Phosphorimager images of dried gels
from one representative experiment where all the chimeras were
tested in parallel. B: The amount of residual IUBK was calculated
for each time of chase as the ratio between the intensity of the
band at the indicated time of chase and the intensity at time 0.
Fig. 6. A long serine containing repeat does not protect IUBK from
TNFK-induced proteolysis. HeLa cells transiently transfected with
HA-tagged IUBK chimeras containing the indicated inserts were cul-
tured for 48 h before treatment with 100 ng/ml TNFK. A: Western
blots of total cell extracts probed the anti-HA mAbs. One represen-
tative experiment out of three. B: The intensity of the speci¢c bands
was quanti¢ed by densitometry. The amount of residual IUBK after
15 min treatment was calculated as the ratio between the intensity
of the speci¢c band in treated and untreated cells. Mean þ S.D. of
three experiments.
FEBS 24963 12-6-01
A. Sharipo et al./FEBS Letters 499 (2001) 137^142140
amino acids was further con¢rmed by the deleterious e¡ect of
substitution of a single alanine with serine. The e¡ect of this
substitution was partially compensated by increasing the
length of the repeat. Remarkably, however, the longer serine
containing repeat could prolong the half-life of IUBK in un-
treated cells but did not protect IUBK from TNFK-induced
proteolysis.
A synthetic eight amino acid long GAr assumes a random
coil conformation in solution and lacks a rigid three-dimen-
sional structure upon fusion to IUBK [30]. It is possible, how-
ever, that its folding may be stabilized by binding to a puta-
tive receptor. The simplest and most attractive model predicts
that the binding domain of the GAr should position its hydro-
phobic residues into three adjacent hydrophobic binding
pockets of the receptor. This can be achieved with repeats
containing glycine spacers of di¡erent length if the peptide
is bound in an extended L-strand conformation. When the
hydrophobic residues are separated by single glycines the pep-
tide may form a regular L-strand where the side chains of the
three hydrophobic residues point in the same direction, result-
ing in a distance between the marginal methyl groups of ap-
proximately 6.3 Aî (Fig. 7A). Longer glycine spacers can be
accommodated in, so-called, L-bulge structures (Fig. 7B,C).
Such L-bulges are found in a variety of proteins [31] and
are in some cases functionally important [32]. For L-bulges
containing two or three glycines, the adjacent side chains of
the hydrophobic residues will be positioned at approximately
the same distance as in regular L-strands whereas the distance
is signi¢cantly increased in L-bulges containing four residues.
It is noteworthy that, while octamers containing three alanines
spaced by one, two or three glycines are present in multiple
copies in the GAr of the prototype B95.8 EBNA1, the 238
amino acid long sequence does not contain four consecutive
glycines. Thus all the possible octamers found in the EBNA1
GAr have the capacity to expose their alanine side chains to
the same hydrophobic receptor site if the fragments bind in an
extended L-strand conformation with L-bulges accommodat-
ing spacer regions of one, two or three glycines.
In accordance with the prediction that at least three hydro-
phobic pockets of the putative receptor must be occupied in
order to achieve inhibition, the GGSGAGAG peptide failed
to prevent the degradation of IUBK in TNFK-treated cells.
Interestingly, the e¡ect of serine substitution could be partly
compensated by increasing the length of the sequence. A mul-
timer of GGSGAGA sequence prevented the degradation of
IUBK in untreated but not in TNFK-treated cells. Conceiv-
ably, putative receptor may contain more than three hydro-
phobic pockets. Occupation of three, non-consecutive pockets
may be su⁄cient to attain low a⁄nity interactions that coun-
teract ‘weak’ but not ‘strong’ degradation signals. We have
recently observed a similar phenomenon using green £uores-
cent proteins (GFP) chimeras targeted for proteolysis by N-
end rule and ubiquitin fusion degradation (UFD) signals of
di¡erent strength, as judged by the half-life of the chimeras
[33]. Chimeras carrying weak degradation signals were e⁄-
ciently protected by short GAr sequences, while longer se-
quences were required to protect chimeras that are degraded
with a rapid turnover. The GGSGAGA peptide is the core
unit of a 54 amino acid long repeat found in the EBNA1-like
protein of the Q-herpesvirus from baboon (baLCV) [34] and a
similar serine containing repeat is also found in the Q herpes-
virus from rhesus monkey (rhLCL) [35]. Consistent with the
possibility that the serine containing repeats may not fully
prevent proteolysis, substitution of the EBNA1 GAr with
the baGAr or rhGAr repeats did not prevent the presentation
of epitopes from EBNA1 to MHC class I restricted CTLs [16].
This may indicate that protection from CTL recognition is
not a conserved function of the repeats. Alternatively, the
presence of serine residues in the GAr-like sequences of pri-
mates may re£ect the adaptation to di¡erent combinatorial
surfaces found in the putative receptors of the endogenous
species. It is noteworthy that a long repeat is also present in
LANA of the second known human Q-herpesvirus, HHV8
[17,18] ; the function of this repeat is presently unknown.
The major known function of EBNA1 is the maintenance
of EBV episomes in proliferating virus-infected cells [36^38].
EBV-infected normal B-cell blasts express, in addition to
EBNA1, numerous viral antigens that are e⁄ciently recog-
nized by EBV-speci¢c immune responses [39^43]. It is, there-
fore, unlikely that failure to present epitopes from EBNA1
would signi¢cantly contribute to their escape from T-cell sur-
Fig. 7. Possible conformation of the GAr bound to a putative re-
ceptor. The £exible nature of the GAr may allow speci¢c interaction
with a putative receptor containing multiple hydrophobic pockets.
GAr with single glycine spacers may assume a regular L-strand con-
formation with a distance between the external methyl groups of
the hydrophobic residues of approximately 6.3 Aî (A). The same dis-
tance between the external methyl groups can be achieved if spacers
of two (B) or three (C) glycines are accommodated in L-bulge struc-
tures. Spacers of four glycines would not allow proper spacing of
the methyl groups. Substitution of one hydrophobic residue would
signi¢cantly weaken the interaction but the e¡ect may be restored
by increasing the length of the repeat if more then three hydropho-
bic pockets are available on the receptor.
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veillance. Conceivably, inhibition of EBNA1 proteolysis by
the GAr may be important in other types of virus^host rela-
tionships that are not recapitulated by infection of primary B-
lymphocytes in vitro. It is also possible that the stabilizing
e¡ect of the GAr may serve a non-immunologic purpose.
Although only a minority of freshly separated EBV carrying
‘resting’ B-lymphocytes appear to express EBNA1 mRNA
[44], a stable EBNA1 protein could persist in these non-pro-
liferating cells in the absence of transcription.
Clearly, much remains to be done to clarify the function of
the GAr in the context of EBV infection. In addition, the
capacity of the GAr to inhibit proteasomal degradation in
cis provides an interesting new tool for the selective stabiliza-
tion of proteins that are degraded by the ubiquitin^protea-
some pathway in vivo. Protection of transduced proteins
from proteasomal degradation, in order to prolong their
half-life or prevent immune recognition, remains an important
task for gene therapy.
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